Reported 1 day ago
Pfizer is acquiring Metsera for $4.9 billion upfront, with the total potentially rising to $7.3 billion based on the success of its anti-obesity drug candidates. Metsera's innovative treatments, including a monthly injection glucagon-like peptide-1 (GLP-1) agonist and a monthly amylin analog, could enhance Pfizer's portfolio in the lucrative obesity market, which is expected to reach $95 billion in sales by 2030. The deal comes as Pfizer faces patent expirations on major drugs, making this acquisition a strategic move to maintain revenue growth.
Source: YAHOO